After the Valor defeat, the group and its partner Biogen will hope that going earlier could improve the amyotrophic lateral sclerosis project’s chances.
Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.
But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
A big selloff on a mid-stage stumble seems harsh, but Takeda has problems on the horizon.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Data on five patients treated with the Crispr therapy EDIT-101 raise doubts about efficacy and safety.
But another safety scare for the big pharma’s Duchenne muscular dystrophy project could be good news for Sarepta.